Consuelo Egla Diana Rabinovich

Professor of Pediatrics

Pediatrics, Rheumatology

rabin001@mc.duke.edu

Box 3212, Durham, NC 27710

2301 Erwin Road, CHC T0909, Durham, NC 27710

More About This Person

At a Glance

Credentials
1. Education
2. Training & Certifications

Academic Experience
1. Current Appointments & Affiliations
2. Previous Appointments & Affiliations

Expertise

Research
1. Research Interests
2. Selected Grants

Publications
1. Selected Publications

Artistic Works / Events

Teaching

Advising & Mentoring

Recognition

Professional Activities

Research Interests

Inflammatory eye disease
Localized scleroderma
Treatment of JIA

Selected Grants

New CARRA Registry

ResearchPrincipal Investigator · Awarded by Childhood Arthritis & Rheumatology Research Alliance, Inc. · 2015 - 2027

A Multicenter, Open-Label Trial of Intravenous Golimumab, a Human Anti-TNF¿ Antibody, in Pediatric Subjects With Active Polyarticular Course Juvenile Idiopathic Arthritis Despite Methotrexate Therapy

Clinical TrialPrincipal Investigator · Awarded by Janssen Research & Development, LLC · 2015 - 2023

Pilot Study for the Implementation of the CARRA Uveitis Consensus Treatment Plans (CTP)

ResearchPrincipal Investigator · Awarded by Childhood Arthritis & Rheumatology Research Alliance, Inc. · 2020 - 2022

Implementation of Electronic Health Record Optimization Tools to Capture and Extract CARRA Data

ResearchPrincipal Investigator · Awarded by Childhood Arthritis & Rheumatology Research Alliance, Inc. · 2020 - 2021

A randomized, double-blind, placebo-controlled, multicenter, phase 3 efficacy and safety study of 2 dose levels of subcutaneious anakinra in patients with Still's disease

Clinical TrialPrincipal Investigator · Awarded by SOBI · 2017 - 2020

An Open-label, Sequential, Ascending, Repeated Dose-finding Study of Sarilumab, Administered with Subcutaneous (SC) Injection, in Children and Adolescents, Aged 1 to 17 Years, with Systemic Juvenile Idiopathic Arthritis (sJIA), Followed by an Extensi

Clinical TrialPrincipal Investigator · Awarded by Sanofi US · 2017 - 2020

An Open-label, Sequential, Ascending, Repeated Dose-finding Study of Sarilumab, Administered with Subcutaneous (SC) Injection, in Children and Adolescents, Aged 2 to 17 Years, with Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA) Followed b

Clinical TrialPrincipal Investigator · Awarded by Sanofi US · 2017 - 2020

Long-Term Extension Study to Evaluate the Safety and Efficacy of Subcutaneous Tocilizumab in Patients with Polyarticular-Course adn Systemic Juvenile Idiopathic Arthritis

Clinical TrialPrincipal Investigator · Awarded by Genentech, Inc. · 2014 - 2018

Training Program in Inflammatory and Immunological Diseases

Inst. Training Prgm or CMEPreceptor · Awarded by National Institutes of Health · 1980 - 2017

Enhancing Clinical Meaningfulness and Usefulness of PROMIS Pediatric Measures Via Validation in Children and Adolescents with Rheumatic Disease, Cancer of Inflammatory Bowel Disease

ResearchPrincipal Investigator · Awarded by University of North Carolina - Chapel Hill · 2016 - 2017

WA28118: Tocilizumab in Systemic JIA

Clinical TrialPrincipal Investigator · Awarded by Genentech, Inc. · 2013 - 2016

CARRA Registry Continuation

ResearchPrincipal Investigator · Awarded by Arthritis Foundation · 2015 - 2015

IDENTIFICATION OF VUR GENES BY COMBINED LINKAGE ANALYSIS AND EXOME SEQUENCING

ResearchInvestigator · Awarded by National Institutes of Health · 2013 - 2015

WA28117: Tocilizumab in Polyarticular-Course JIA

Clinical TrialPrincipal Investigator · Awarded by Genentech, Inc. · 2013 - 2015